Recent 8-K filings for LTRN
Highest-materiality recent filing
Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer
- Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
- R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.
-
Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300
Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.
-
Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
-
Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform
Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.
-
Lantern Pharma demonstrates withZeta.ai AI co-scientist platform; no financial data disclosed
Live demo of withZeta.ai, a multi-agentic AI platform for rare cancer drug discovery and clinical design.
-
Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances
Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
-
Lantern Pharma demonstrates AI tools for rare cancers at Jan 22 event
Event hosted on Jan 22, 2026 to showcase initial AI tools and multi-agentic system for rare cancers.
-
Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate
Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
-
All six director nominees elected: Keyser (2.21M for), Sharma (2.21M), Chandru (2.20M), Maccecchini (2.21M), Schalop (2.21M), Silberstein (2.21M); broker non-votes 5.19M.
-
Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
-
Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%
Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.
-
Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity
ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.
-
Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025
Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
-
Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances
Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
-
Lantern Pharma amends CSO Bhatia's agreement: term to Jan 2026, reduced hours, $189,600 salary
Kishor G. Bhatia, CSO, employment term extended to January 15, 2026.
-
Lantern Pharma Q3 2024 earnings call held; no financial details in 8-K
Conference call and live webinar occurred on November 7, 2024 for Q3 results.
-
Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in
Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
-
Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR
Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
-
Stockholders approve all proposals at 2024 annual meeting
Five directors elected: Keyser, Sharma, Chandru, Maccecchini, Silberstein; each received ~3.04M votes for, ~22K withheld.
-
Lantern Pharma amends bylaws to streamline director count setting
Board of Directors approved amendment to Section 3.02 of Bylaws on May 23, 2024, effective immediately.
-
Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance
Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.
-
Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance
Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event earnings